Volkmar Müller

Research interests

Publications

• Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

  Nature Medicine · 2024 · https://doi.org/10.1038/s41591-024-03261-7

• Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

  Journal of Clinical Oncology · 2020 · https://doi.org/10.1200/jco.20.00775

• Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.05.015

• Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1914609

• Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis

  JNCI Journal of the National Cancer Institute · 2018 · https://doi.org/10.1093/jnci/djy152

• Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

  BMC Medicine · 2018 · https://doi.org/10.1186/s12916-018-1163-y

• Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer

  JAMA Oncology · 2017 · https://doi.org/10.1001/jamaoncol.2017.1007

• Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu364

• Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study

  Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.45.6335

• HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer

  Breast Care · 2013 · https://doi.org/10.1159/000346837

• Treatment of breast cancer during pregnancy: an observational study

  The Lancet Oncology · 2012 · https://doi.org/10.1016/s1470-2045(12)70261-9

• Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

  Journal of Clinical Oncology · 2011 · https://doi.org/10.1200/jco.2010.31.4930

• A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

  Clinical Cancer Research · 2011 · https://doi.org/10.1158/1078-0432.ccr-11-0926

• Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients

  Gynecologic Oncology · 2011 · https://doi.org/10.1016/j.ygyno.2011.04.039

• Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial

  Clinical Cancer Research · 2010 · https://doi.org/10.1158/1078-0432.ccr-09-2042

• HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial

  Breast Cancer Research and Treatment · 2010 · https://doi.org/10.1007/s10549-010-1163-x

• Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System

  Clinical Cancer Research · 2007 · https://doi.org/10.1158/1078-0432.ccr-06-1695

Current projects

No projects listed.